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Abstract
Background: Many patients with bronchiectasis have recurrent hospitalisations for infective exacerbations. Acute
kidney injury (AKI) is known to be associated with increased in-hospital mortality. This study examined the frequency of
AKI, associated risk-factors, and the association of AKI with in-hospital mortality among patients with bronchiectasis.
Methods: Anonymised data of patients with non-cystic fibrosis bronchiectasis from the UK Clinical Practice Research
Datalink, linked to Hospital Episode Statistics, were used to identify hospitalisations with a primary diagnosis of lower
respiratory tract infection (LRTI), from 2004 to 2013. After estimating the proportion of AKI diagnoses, a multivariable
logistic regression model was constructed to investigate which background factors were associated with AKI.
In-hospital mortality was compared between hospitalisations with and without an AKI diagnosis, with
subsequent logistic regression analyses carried out for the association between AKI and in-hospital mortality.
Results: Of 7804 hospitalisations due to LRTI observed in 3477 patients with bronchiectasis, 230 hospitalisations
involved an AKI diagnosis, an average of 2.9 %. However, the percentage increased from less than 2 % in
2004 to nearly 5 % in 2013. After taking this temporal change into account, AKI was independently associated
with older age, male sex, decreased baseline kidney function, previous history of AKI, and a diagnosis of sepsis. In-hospital
mortality was 33.0 % (76/230) and 6.8 % (516/7574), in hospitalisations with and without AKI, respectively (P < 0.001). After
adjustment for confounding factors, diagnosis of AKI remained associated with in-hospital mortality (Odds ratio
5.52, 95 % confidence interval: 3.62-8.42).
Conclusions: Among people with bronchiectasis hospitalised for infective exacerbations, there is an important
subgroup of patients who develop AKI. These patients have substantially increased in-hospital mortality and therefore
greater awareness is needed.
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Background
Bronchiectasis, a syndrome of airway dilatation and
bronchial wall thickening, has been increasing in preva-
lence in the community [1, 2]. A UK study showed that
the period prevalence of non-cystic fibrosis (CF) bron-
chiectasis was 0.7 % over the 8-year period from 2004
to 2011, and that its overall incidence has increased
from 18/100,000 in 2004 to 32/100,000 person-years at
risk in 2011 [2]. Some patients with bronchiectasis experi-
ence infective exacerbations due to impaired respiratory
drainage and immune function. Although short- and long-
term use of antibiotics, such as nebulised gentamicin, has
been reported to be effective in reducing airway inflamma-
tion [3, 4], hospital care is recommended for severe cases
according to the British Thoracic Society guideline for
non-CF bronchiectasis [5].
Acute kidney injury (AKI), previously known as acute
renal failure, can be precipitated by a range of triggers
and is common among hospitalised patients [6]. AKI is
associated with a poorer prognosis, including among pa-
tients with community acquired pneumonia [6–8]. It is
anticipated that patients with bronchiectasis would have
a number of risk factors for AKI including the develop-
ment of sepsis as a result of infectious exacerbations and
frequent exposure to antibiotics such as gentamicin, a
drug with nephrotoxic potential.
However, to the best of our knowledge, there has
been no published study of AKI among patients with
bronchiectasis. Therefore, using a UK nationwide out-
patient database linked to inpatient data, we aimed to
investigate the proportion of patients that develop AKI,
the risk factors and the association between AKI and
in-hospital mortality among patients with infective ex-
acerbations of bronchiectasis.
Methods
Data source
The Clinical Practice Research Datalink (CPRD) is the
National Health Service (NHS)’s observational data and
interventional research service [9]. The database in-
cludes the following data: patient demographics; coded
diagnoses with dates; prescriptions; laboratory test re-
sults; and referrals made by general practitioners (GPs).
The CPRD can be linked with Hospital Episode Statistics
(HES), which contains details of all admissions to NHS
hospitals in England [10]. HES data consist of main and
subsidiary diagnoses, coded using the 10th revision of
International Classification of Disease (ICD-10) [11], and
admission and discharge dates with discharge status
(dead or alive). Approximately 60 % of CPRD practices
have consented to linkage with HES. For this study, we
used the CPRD linked to the latest HES dataset between
1st April 1997 and 31st March 2014. This dataset
includes nearly 10 million patient records in 398 GP
practices. Identification of diseases and prescriptions was
based on diagnosis codes (Read codes) and product
codes in the CPRD and ICD-10 codes in the HES. The
list of Read codes and products codes used for this study
is available on request from the authors.
Informed consent was waived for CPRD data because
the data are anonymously extracted. Ethical approval for
this study was obtained from the Independent Scientific
Advisory Committee, which oversees research involving
CPRD data (Protocol 14_127RA), as well as from the
London School of Hygiene and Tropical Medicine ethics
committee (reference: 7355).
Study population and identification of hospital episodes
We identified adult patients with non-CF bronchiectasis
within the CPRD at any time in the 10-year period be-
tween 1st April 2004 and 31st March 2014. The start
date was chosen because the first unified criteria for AKI
were established in 2004 [12]. Included patients began
follow-up at the latest time-point of: the patient’s 18th
birthday; the date bronchiectasis was first coded, one
year after patients’ registration at a practice, the date the
practice reached CPRD quality control standards; or 1st
April 2004. The follow-up period ended at the first time-
point of: death; the patient leaving the practice; the last
data collection from the practice; or 31st March 2014.
We defined infective exacerbation of bronchiectasis
as hospitalisation with lower respiratory tract infections
(LRTIs). ICD-10 codes suggestive of LRTI (including
pneumonia, but excluding chronic obstructive pulmon-
ary disease (COPD) exacerbation) were pre-specified:
J12, J13, J14, J15, J16, J17, J18, J20, J21, J22, and J47.
We included all hospitalisations with these ICD-10 codes
as a primary diagnosis, during the follow-up period for
each patient. We excluded hospitalisations after the devel-
opment of end-stage renal disease (ESRD), or chronic kid-
ney disease (CKD) stage 5 (estimated glomerular filtration
rate (eGFR) <15 mL/min/1.73 m2) [13].
Variables
The gold-standard criteria for defining AKI are changes
in creatinine in relation to baseline, or changes in urine
output. The first global criteria for AKI (acute renal fail-
ure at that time) were established in 2004 [12]: We did
not have access to biochemical data during hospitalisa-
tion and therefore defined hospitalisations with AKI
using the following ICD-10 codes: N17.0, N17.1, N17.2,
N17.8 and N17.9, regardless of the code position (i.e.,
secondary diagnosis or lower order, while a primary
diagnosis had to be a LRTI code).
We pre-specified potential risk factors for a diagnosis
of AKI which could be confounding factors in the asso-
ciation between AKI diagnosis and in-hospital mortality.
In addition to sex and smoking status, we included 10
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out of 14 general risk factors for AKI (Table 1), which
were proposed in the recent National Institute for
Health and Care Excellence (NICE) guidance [14]. For
baseline kidney function, we calculated eGFR from serum
creatinine value recorded in the CPRD, using Chronic
Kidney Disease Epidemiology Collaboration equation [15],
and categorized them according to NICE guidance for
CKD [13]. Finally, we included co-diagnosis of COPD, be-
cause there is a close association between COPD and bron-
chiectasis [16, 17], and COPD is associated with AKI [18].
Statistical analysis
We calculated the proportion of patients diagnosed with
AKI among hospitalisations with LRTI overall, and then
by financial year, considering that the identification of
AKI in hospitals and the recording practice in the HES
may have changed over time. For characteristics of hos-
pitalisations with and without AKI, descriptive statistics
were presented as percentages for all variables, with
Chi-square (χ2) tests to examine differences between
groups. Multivariable logistic regression analysis was then
performed to examine which factors were associated with
the diagnosis of AKI, taking year into account. In-hospital
mortality was then compared between hospitalisations
with and without AKI, with χ2 tests. Kaplan-Meier
survival curves were plotted. Finally, we conducted
multivariable logistic regression analyses of the association
between AKI diagnosis and in-hospital mortality. Follow-
ing an estimation of age-sex adjusted odds ratio, all the
covariates defined above were entered into the multivari-
able regression model. In order to take into account the
fact that many patients were repeatedly hospitalised, a
random effect model was used for all logistic regression
analyses. A small number of cases with missing smoking
status were excluded. A P value of < .05 was inferred as
statistically significant. All statistical analyses were con-
ducted using Stata 13 software (Stata Corp, Texas).
Sensitivity analysis
To treat potential uncertainties of the data in CPRD and
HES, we conducted sensitivity analyses under the follow-
ing three scenarios to examine whether there would be a
marked change in the conclusion regarding the associ-
ation between AKI diagnosis and in-hospital mortality:
(i) we excluded patients without baseline eGFR data, be-
cause absence of information on outpatient kidney func-
tion may be associated with whether or not AKI is
diagnosed by the responsible clinicians; (ii) we excluded
patients with co-diagnosis of COPD, because bronchiec-
tasis diagnosed in the context of COPD follow-up may
be different from bronchiectasis diagnosed on its own;
(iii) we limited the hospitalisations to those with a
Table 1 List of risk factors for acute kidney injury selected and defined for the study
Risk factors proposed in NICE guidance for AKI Definition in the current study
- Chronic kidney disease (eGFR < 60 mL/min/1.73 m2) - Outpatient eGFRa categorised into groups: > 60, 45–60, 30–45, and 15–30 mL/
min/1.73 m2, and “No measurement” allocated if serum creatinine had not
been measured for the past 2 years prior to the hospitalisation for LRTI.
- Heart failure - Diagnosis of heart failure, recorded in CPRD before the hospitalisation for LRTI
- Liver disease - Diagnosis of cirrhosis in CPRD, as a representative code for liver disease
- Diabetes - Diagnosis of diabetes in CPRD
- History of AKI - Diagnosis of AKI in CPRD or any hospitalisations with diagnosis of AKI in HES
- Oliguria (urine output < 0.5 mL/kg/h) (Not obtained in the database)
- Neurological or cognitive impairment or disability, which may
mean limited access to fluids because of reliance on a carer
- Diagnosis of dementia in CPRD, as a representative condition
- Hypovolaemia (Not obtained in the database)
- Use of drugs with nephrotoxic potential (such as NSAIDs,
aminoglycosides, ACEI, ARBs, and diuretics)
- NSAIDs, aminoglycosides (products for injection and nebuliser), ACEI or ARBs,
and diuretics (loop, thiazide, and potassium-sparing diuretics), prescribed for
the past 3 months prior to the hospitalisation for LRTI
- Use of iodinated contrast agents (Not obtained in the database)
- Symptoms or history of urological obstruction or conditions that
may lead to obstruction
- Diagnosis of prostatic hypertrophy in CPRD, as a representative condition
- Sepsis - Sepsis identified as an additional diagnosis code of sepsis in HES during the
hospitalisation for LRTI
- Deteriorating early warning scores (Not obtained in the database)
- Age (≥ 65 years) - Age categorised into groups: < 65, 65–74, 75–84, and > 85
ACEI, angiotensin converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin II receptor blocker; CPRD, Clinical Practice Research Datalink; eGFR,
estimated glomerular filtration rate; LRTI, lower respiratory tract infection; HES, Hospital Episode Statistics; NICE, National Institute for Health and Care Excellence;
NSAIDs, non-steroidal anti-inflammatory drugs
aBased on the most recent creatinine measurement, excluding those just before admission (within 28 days)
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primary diagnosis of pneumonia (ICD-10 codes J12, J13,
J14, J15, J16, J17, and J18), because these cases are likely
to be more severe and definitive among the cases of
LRTI we have included.
Results
Figure 1 shows the workflow by which eligible hospital
episodes were identified. Of 16,214 patients with non-CF
bronchiectasis registered in the HES-linked CPRD be-
tween 01/04/2004 and 31/3/2014, 3504 patients had at
least one hospitalisation for LRTI, a total of 7873 hospi-
talisations. The median number of hospitalisations per
patient during the follow-up period was two, with an
interquartile range of 1–4. We excluded 69 hospitalisa-
tions that occurred after the development of ESRD. Of
the remaining 7804 hospital episodes, 230 hospitalisa-
tions involved AKI diagnoses, accounting for 2.9 %
(95 % confidence interval [CI]: 2.6-3.3 %). Fig. 2 illus-
trates the annual change in the proportion of AKI diag-
nosis from 1st April 2004 to 31st March 2014. The
percentage increased, from 1.8 % (8/475 hospitalisations)
in 2004 to 4.7 % (54/1096 hospitalisations) in 2013.
Table 2 compares patient characteristics between hos-
pitalisations with and without AKI. Patients with an AKI
diagnosis were more likely to be male and were older
than those without an AKI diagnosis. The proportion of
patients with a history of current or previous smoking
and co-diagnosis of COPD were higher in those with an
AKI diagnosis. The baseline kidney function was worse
in patients admitted with AKI: nearly half had an eGFR
less than 60 mL/min/1.73 m2 in the group with an AKI
diagnosis, while only around 15 % of patients without
AKI had an eGFR less than 60 mL/min/1.73 m2. Previ-
ous history of: heart failure, diabetes, AKI, dementia and
prostatic hypertrophy, as well as recent prescription of:
non-steroidal anti-inflammatory drugs (NSAIDs), amino-
glycoside nebuliser, angiotensin converting enzyme inhibi-
tors (ACEI) or angiotensin II receptor blockers (ARBs),
diuretics, and a concurrent diagnosis of sepsis, were more
frequent in those with AKI than in those without AKI.
Table 3 shows the results of multivariable logistic regres-
sion analysis. Older age, male sex, decreased baseline
eGFR, history of AKI, and sepsis diagnosis, were inde-
pendently associated with the diagnosis of AKI.
Overall in-hospital mortality was 7.6 % (592/7804 hos-
pitalisations). In hospitalisations with and without an
AKI diagnosis, in-hospital mortalities were 33.0 % (76/
230) and 6.8 % (516/7574), respectively (P < 0.001).
Kaplan-Meier survival curve by AKI status demonstrates
that patients with an AKI diagnosis had higher cumula-
tive mortality, compared with those without an AKI
diagnosis (Fig. 3). Multivariable logistic regression re-
vealed that AKI diagnosis was positively associated with
in-hospital mortality, with an age-sex adjusted odds ratio
of 6.72 (95 % CI: 4.45-10.15), and an adjusted odds ratio
of 5.52 (95 % CI: 3.62-8.42) after adjustment for all the
covariates (Table 4). Table 4 also shows the results of
sensitivity analyses. A positive association between AKI
diagnosis and in-hospital mortality was consistently
demonstrated in the three different scenarios.
Discussion
This study examined the burden of AKI among patients
with non-CF bronchiectasis. Among approximately
16,000 patients with a diagnosis of non-CF bronchiec-
tasis, over 20 % experienced at least one hospitalisation
for LRTI during the observation period, much higher
than that observed in the general population [19]. Of
those who developed AKI during hospitalisation for
Fig. 1 Flow chart for the selection of eligible hospitalisations with
and without acute kidney injury diagnosis. AKI, acute kidney injury;
CF, cystic fibrosis; ESRD, end stage renal disease
Fig. 2 Annual change in the proportion of acute kidney injury
diagnosis during hospitalisation. AKI, acute kidney injury
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LRTI, one third died. The strong association of AKI
diagnosis with mortality (fully adjusted odds ratio 5.52
(95 % CI: 3.62-8.42)) has important implications for the
clinical care of patients with bronchiectasis.
Given the high prevalence of risk factors for AKI
among patients with bronchiectasis, the incidence of
AKI found in this study was surprisingly low. A previous
study, which defined AKI based on changes in serum
creatinine values [12], reported that the incidence of
AKI determined at admission was 18 % among patients
hospitalised for community-acquired pneumonia [8].
Another study in the US found that 34 % of patients
with community acquired pneumonia developed AKI
during hospitalisation [7]. The diagnosis of AKI in this
study depended upon recognition and diagnosis by the
responsible clinicians, as well as subsequent coding of
that diagnosis. A lower incidence of AKI obtained by
coded diagnosis compared to that based on biochemical
values is well established [20], but the size of the dis-
crepancy in this study suggests that awareness of, and
Table 2 Comparison of patient characteristics between hospitalisations for lower respiratory tract infection with and without acute
kidney injury
Hospitalisations withAKI diagnosis (N = 230) (%) Hospitalisations without AKI diagnosis (N = 7574)(%) P Value
Age (years) < 0.001
< 65 10.9 31.4
65-74 22.2 29.2
75-84 41.7 27.9
≥ 85 25.2 11.5
Sex (Male) 53.0 36.3 < 0.001
Smoking history 0.037
Non-smoker 28.7 37.7
Ex-smoker 59.6 53.4
Current smoker 11.3 8.6
Missing 0.4 0.3
Co-diagnosis of COPD 60.4 50.0 0.002
Outpatient eGFR (mL/min/1.73 m2) <0.001
> 60 33.0 53.8
45-60 17.4 11.0
30-45 21.3 4.2
15-30 10.0 1.3
No measurement 18.3 29.8
History of AKI 20.4 4.4 < 0.001
Chronic conditions
Heart failure 19.6 9.0 < 0.001
Cirrhosis 0.9 0.6 0.638
Diabetes 26.1 13.1 < 0.001
Dementia 4.8 2.9 0.107
Prostatic hypertrophy 17.0 7.5 < 0.001
Drugs with nephrotoxic potential
NSAIDs 28.3 22.5 0.038
Aminoglycoside nebuliser 1.3 0.1 0.001
Aminoglycoside injection 1.3 0.7 0.227
ACEI or ARBs 35.2 21.9 < 0.001
Diuretics 44.8 29.5 < 0.001
Sepsis diagnosis 12.2 1.0 < 0.001
ACEI, angiotensin converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; eGFR,
estimated glomerular filtration rate; NSAIDs, non-steroidal anti-inflammatory drugs
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therefore diagnosis of, AKI may be still low among clini-
cians caring for this patient group. The increased inci-
dence of AKI over time is likely to reflect at least in part
growing awareness of the condition among clinicians, in-
fluenced by the publication of international guidelines
and awareness campaigns [12, 21, 22].
Previously identified risk factors including older age,
male sex, baseline kidney function, previous history of
AKI, and sepsis diagnosis were independently associated
with AKI diagnosis in this setting. The strongest associ-
ation was for patients concurrently diagnosed with sep-
sis, with an odds ratio of 18.32 (95 % CI: 10.04-33.41),
compatible with findings in previous studies [7, 8], and
pathophysiological considerations [23]. Similarly CKD,
known to be a major risk factor for AKI [24–26], was as-
sociated with increased odds of AKI in a stepwise fash-
ion according to more advanced CKD stages.
To our knowledge this is the first study examining the
diagnosis and outcome of AKI among patients with
bronchiectasis, and has a number of strengths including
a large, nationally representative sample of patients over
a ten year period. The linkage between the outpatient
and inpatient data allowed for quantification of the effect
size of a number of risk factors and adjustment for im-
portant confounders of the association between AKI and
in-hospital mortality.
Several limitations of this study must be acknowl-
edged. Firstly, it uses routinely collected data and some
variables may be misclassified. The diagnosis of bronchi-
ectasis is predominantly made by respiratory physicians
based on objective findings such as a chest CT scan, and
subsequently entered into the primary care record by a
GP [5, 27]. Therefore, the specificity of bronchiectasis
diagnosis is expected to be high. However, no validation
study between CPRD and patient records for bronchiec-
tasis has been conducted to date. The definition of AKI
is based on the presence of a relevant ICD-10 code in
HES, and was not validated by creatinine values or urine
volume. However, a single centre study in the UK dem-
onstrated that, where present, an AKI code in HES had
a 95 % positive predictive value compared with current
biochemical definitions of AKI [28]. In Scotland, the
proportion of biochemical cases of AKI also identified
by coding increased markedly with greater severity of
Table 3 Multivariable logistic regression analysis for factors
associated with diagnosis of acute kidney injury
Adjusted odds
ratioa
95 % confidence
interval
Age (years old)
<65 Reference
65-74 1.49 0.87 – 2.57
75-84 2.26 1.34 – 3.80
≥85 2.64 1.48 – 4.68
Sex (Male/Female) 1.75 1.23 – 2.49
Smoking history
Non-smoker Reference
Ex-smoker 0.94 0.65 – 1.35
Current smoker 1.50 0.87 –2.58
Co-diagnosis of COPD (Yes/No) 1.18 0.85 – 1.63
Outpatient eGFR (mL/min/
1.73 m2)
> 60 Reference
45-60 2.44 1.54 – 3.86
30-45 7.42 4.46 – 12.34
15-30 10.73 5.35 – 21.53
No measurement 1.55 0.99 – 2.42
History of AKI (Yes/No) 1.93 1.23 – 3.03
Chronic conditions (Yes/No)
Heart failure 1.06 0.69 – 1.63
Cirrhosis 1.50 0.25 – 9.16
Diabetes 1.38 0.94 – 2.02
Dementia 0.92 0.44 – 1.93
Prostatic hypertrophy 1.28 0.79 – 2.08
Drugs with nephrotoxic potential
(Yes/No)
NSAIDs 0.95 0.66 – 1.36
Aminoglycosides nebuliser 6.15 0.43 – 87.59
Aminoglycosides injection 3.90 0.98 – 15.58
ACEI or ARBs 1.34 0.94 – 1.92
Diuretics 1.19 0.84 – 1.70
Sepsis diagnosis (Yes/No) 18.32 10.04 – 33.41
ACEI, angiotensin converting enzyme inhibitor; AKI, acute kidney injury; ARB,
angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease;
eGFR, estimated glomerular filtration rate; NSAIDs, non-steroidal
anti-inflammatory drugs
aAdditionally adjusted by financial year of hospitalisation
Fig. 3 Kaplan-Meier survival curves by the status of acute kidney
injury diagnosis. AKI, acute kidney injury
Iwagami et al. BMC Pulmonary Medicine  (2016) 16:14 Page 6 of 8
AKI [20]. Therefore while this study may have detected
a minority of true AKI cases, those identified are likely
to be valid and at the severe end of the spectrum. Simi-
larly, it is likely that patients identified to have sepsis
from HES coding data were more severe cases. Secondly,
although we were able to adjust for many known risk
factors for AKI, unmeasured confounding is possible.
For example, access to local nephrology services could
have affected both the likelihood of being diagnosed
with AKI as well as in-hospital mortality [29]. Finally, al-
though this study has the largest sample size examined
to date, the statistical power was low for identification of
risk factors with small effect sizes, and this may partly
explain why variables such as the prescription of drugs
with nephrotoxic potential were not identified as inde-
pendent risk factors for AKI.
Conclusions
This nationwide study is the first to investigate the risk
factors for and outcomes of AKI among patients with
bronchiectasis hospitalised for infective exacerbations.
AKI was infrequently diagnosed but was strongly associ-
ated with mortality. A national programme is currently
underway to improve outcomes from this preventable and
treatable condition [30]. These results suggest that there
needs to be a greater awareness of, and possibly better
treatment of AKI among clinicians caring for patients with
bronchiectasis to improve these poor outcomes.
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